RPRuth PlummerMDSlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019Changes and Challenges in Early Phase Trial Endpoints - Ruth Plummer, MDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019New Designs for Early Clinical Trials of IO Drugs - Emiliano Calvo, Md, PhDView Slideset
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Protein binding determination of second-line anti-tuberculosis drugs in vitro using an ultrafiltration techniqueView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Comparison of a Bayesian forecasting algorithm handling inter-occasion variability and a linear regression approach for dose individualization of rifampicinView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Mathematical modeling using in vitro checkerboard assay data: Clofazimine as a potentially synergistic anti-TB drugView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Levofloxacin urine kinetics and development of a colorimetric assay for therapeutic drug monitoring among people living with HIV and TBView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Optimal dose individualisation of rifampicin needs to account for between-occasion variabilityView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis PatientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Mechanistic modelling of time-to-positivity and colony-forming unit in tuberculosis patients on high-dose rifampicin to improve understanding of biomarker relationView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Drug effect of clofazimine on persistent mycobacteria explain an unexpected increase of bacterial load in patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Stratified dosage regimens from early bactericidal activity studies: an application to pretomanidView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019A PBPK modelling approach to simulate the rifampicin-moxifloxacin drug-drug interaction in TB patientsView Abstract
